The Phase 1 data are supportive but early-stage; they do not alter the near-term commercial outlook for vamorolone in DMD. Monitor for any subsequent regulatory filings or partnership announcements that could signal life-cycle expansion into new indications.
Price Chart
Executive Summary
Catalyst Pharmaceuticals announced topline results from a Phase 1 study of vamorolone (AGAMREE) showing balanced corticosteroid activity with glucocorticoid effects but without significant immunosuppression at clinical doses. The data support the drug's current DMD dosing and potential expansion into other chronic inflammatory rare diseases, though no near-term regulatory or financial impact is expected.
Key Facts
- Phase 1 study in healthy adults showed vamorolone and deflazacort had comparable cortisol suppression at clinical doses.
- Vamorolone demonstrated less pronounced immunosuppressive biomarker effects than deflazacort in Part A.
- In Part B, clinically relevant immunosuppression was observed only at the highest dose (40 mg/kg/day), which is above approved dosing.
- No relevant immunosuppressive effects were seen at lower doses (9 or 27 mg/kg/day).
- The data support vamorolone's potential utility across a broad range of chronic inflammatory rare diseases.
Financial Impact
No financial figures reported; the filing is a clinical data update with no immediate revenue or cost impact.
Risk Factors
- No guarantee that vamorolone will receive regulatory approval for additional indications.
- Competition from other corticosteroids and anti-inflammatory therapies could limit market opportunity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-290768 |
| Document: d158010dex991.htm | 0001193125-26-290768 |
| Document: 0001193125-26-290768-index-headers.html | 0001193125-26-290768 |
| Document: 0001193125-26-290768-index.html | 0001193125-26-290768 |
| Document: 0001193125-26-290768.txt | 0001193125-26-290768 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access